Minimal Change Disease Clinical Trials

27 clinical trials for Minimal Change Disease across international registries, including 13 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases — RECRUITING · PHASE2
• Study of WAL0921 in Patients With Glomerular Kidney Diseases — RECRUITING · PHASE2
• A Trial to Assess the Efficacy and Safety of Obinutuzumab in Treating Adults With Minimal Change Disease (MCD) — RECRUITING · PHASE2
• NEPTUNE Match Study — RECRUITING · NA
• Nephrotic Syndrome Study Network — RECRUITING
• Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases — RECRUITING · PHASE2
• Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease — RECRUITING
• A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS) — RECRUITING · NA
• taVNS for FRNS in Children — RECRUITING · NA
• A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis — RECRUITING · PHASE2
• Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome. — RECRUITING
• The FOrMe Registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry) — RECRUITING
• KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis — RECRUITING
• Immunophenotyping Profiling in Patients With Primary Nephrotic Syndrome — COMPLETED
• Active Vitamin D And Reduced Dose Prednisolone for Treatment in Minimal Change Nephropathy — COMPLETED · PHASE4
• Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease — COMPLETED · PHASE2
• Efficacy and Safety of Tacrolimus in Combination With Ripertamab in the Initial Treatment of Patients With MCD — NOT_YET_RECRUITING · PHASE3
• Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS) — TERMINATED · PHASE2
• Circulating Factors in Nephrotic Syndrome — NOT_YET_RECRUITING
• A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN) — TERMINATED
• Tacrolimus Versus Prednisolone for the Treatment of Minimal Change Disease — COMPLETED · PHASE4
• Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD) — COMPLETED · PHASE2
• Rituximab for Refractory or Relapsed Focal Segmental Glomerulosclerosis or Minimal Change Disease — COMPLETED
• Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome — OTHER · PHASE3
• Diagnostic Value of Linked Color Imaging for Minimal Change Esophagitis in Nonerosive Reflux Esophagitis and GERD — OTHER
• Valproic Acid for Idiopathic Nephrotic Syndrome — OTHER · PHASE2
• Therapeutic Effect of Tacrolimus in Combination With Low Dose Corticosteroid in Adult Patient With Minimal Change Nephritic Syndrome — COMPLETED · PHASE2

Refine this search